– UK, Cambridge – Abcam plc (LON:ABC), a global leader in the supply of life science research tools, is today announced the appointment of Giles Kerr as a non-executive Director with effect from 12 December 2018.
Peter Allen, Chairman of Abcam said: “I am delighted Giles is joining the Board of Abcam. Giles brings a wealth of experience within the life science sector, finance and a first-hand understanding of our academic research customers. He will make a valuable contribution to our Board.”
About Giles Kerr
Giles has extensive experience as an executive and non-executive Director in a wide range of public and private organisations. He recently stepped down as Finance Director of Oxford University, a position he had held since 2005. He remains a non-executive Director of Arix Biosciences plc, Adaptimmune Therapeutics plc, Senior plc, PayPoint plc as well as Oxford Sciences Innovation. From 1990 to 2004 Giles held a number of roles at Amersham plc, including Group Finance Director. Giles is a graduate in Economics from the University of York and a Chartered Accountant.
Giles Kerr commented: “I have known and admired Abcam’s business for many years and am proud to be able to join the team. I look forward to working with the Board as the Company continues to execute on its strategy and build on its position as global leader.”
Giles will join the Audit & Risk Committee.
About Abcam plc
As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life sciences, Abcam’s ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world’s 750,000 life science researchers use Abcam’s affinity binders, reagents, biomarkers and assays and the Company’s products are mentioned in over 20,000 of the c.56,000 peer-reviewed papers published each year in the life sciences.
By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.
Abcam’s eleven locations are in the world’s leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 130 countries. Abcam was admitted to AIM in 2005 (LON:ABC).
For more information : https://www.abcam.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.